Results 31 to 40 of about 175,639 (315)

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers. [PDF]

open access: yes, 2019
For long, the treatment of locoregionally advanced laryngeal and hypopharyngeal squamous cell cancers (SCC) consisted of either total laryngectomy (TL) or definitive radiotherapy (RT).
Argiris, Athanassios   +1 more
core   +2 more sources

DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report

open access: yesPharmaceutics, 2019
5-Fluorouracil remains a foundational component of chemotherapy for solid tumour malignancies. While considered a generally safe and effective chemotherapeutic, 5-fluorouracil has demonstrated severe adverse event rates of up to 30%.
Theodore J. Wigle   +3 more
doaj   +1 more source

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

open access: yes, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis   +10 more
core   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

open access: yesHepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou   +13 more
wiley   +1 more source

5-Fluorouracil/Coumarin and 5-Fluorouracil/Chromone Hybrids: Synthesis and Drug-Likeness Modeling

open access: yesMolbank
A series of 5-fluorouracil/coumarin and 5-fluorouracil/chromone hybrids were synthesized with good yields using click chemistry as the key step.
Laura Giraldo-Arroyave   +2 more
doaj   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

open access: yes, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta   +4 more
core   +1 more source

Investigation of the Electrochemical Interaction Behavior of DNA with 5-Fluorouracil Derivatives

open access: yesInternational Journal of Electrochemical Science, 2011
Although many 5-Fluorouracil derivatives have been synthesized and identified, there are few reports on the interaction modes of different anti-carcinogen 5-Fluorouracil derivatives with Deoxyribonucleic acid (DNA).
Ke-jun Zhang, Wu-yi Liu
doaj   +1 more source

Comparative study of actinic keratosis treatment with 3% diclofenac sodium and 5% 5-fluorouracil [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2013
BACKGROUND: Actinic keratosis is a frequent lesion which occurs in sunlight exposed areas. Diclofenac sodium and 5-Fluorouracil are effective, non-invasive and easy-to-apply topical treatment options.
Majorie Mergen Segatto   +3 more
doaj   +1 more source

Efficacy of Combined 5-Fluorouracil and Photodynamic Therapy in Glioma Spheroids

open access: yes, 2018
Standard treatment regimens consisting of surgery, radiation and chemotherapy have proven ineffective for the treatment of high-grade gliomas such as glioblastoma multiforme (GBM).
Singh, Karanjit
core   +1 more source

Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. [PDF]

open access: yes, 2014
A tumor-selective non-lytic retroviral replicating vector (RRV), Toca 511, and an extended-release formulation of 5-fluorocytosine (5-FC), Toca FC, are currently being evaluated in clinical trials in patients with recurrent high-grade glioma (NCT01156584,
Gruber, Harry E   +11 more
core   +2 more sources

Home - About - Disclaimer - Privacy